[1]
|
Feng, R.-M., Zong, Y.-N., Cao, S.-M. and Xu, R.-H. (2019) Current Cancer Situation in China: Good or Bad News from the 2018 Global Cancer Statistics? Cancer Communications, 39, 1-12.
https://doi.org/10.1186/s40880-019-0368-6
|
[2]
|
Japanese Gastric Cancer Association (2011) Japanese Classifica-tion of Gastric Carcinoma: 3rd English Edition. Gastric Cancer, 14, 101-112. https://doi.org/10.1007/s10120-011-0041-5
|
[3]
|
Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X.Q. and He, J. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338
|
[4]
|
Liu, C.-T., Hong, C.-Q., Huang, X.-C., Li, E.-M., Xu, Y.-W. and Peng, Y.-H. (2020) Blood-Based Markers in the Prognostic Prediction of Esophagogastric Junction Cancer. Journal of Cancer, 11, 4332-4342.
https://doi.org/10.7150/jca.44545
|
[5]
|
Liu, H.N., Yao, C., Wang, X.F., Zhang, N.P., Chen, Y.J., Pan, D., Zhao, G.P., Shen, X. Z., Wu, H. and Liu, T.T. (2023) Diagnostic and Economic Value of Carcinoembryonic Antigen, Carbo-hydrate Antigen 19-9 and Carbohydrate Antigen 72-4 in Gastrointestinal Cancers. World Journal of Gastroenterology, 29, 706-730.
https://doi.org/10.3748/wjg.v29.i4.706
|
[6]
|
Kim, J., Beidler, P., Wang, H., Li, C., Quassab, A., Coles, C., Drescher, C., Carter, D. and Lieber, A. (2020) Desmoglein-2 as a Prognostic and Biomarker in Ovarian Cancer. Cancer Biology & Therapy, 21, 1154-1162.
https://doi.org/10.1080/15384047.2020.1843323
|
[7]
|
Saito, M., Tucker, D.K., Kohlhorst, D., Niessen, C.M. and Kowalczyk, A.P. (2012) Classical and Desmosomal Cadherins at a Glance. Journal of Cell Science, 125, 2547-2552. https://doi.org/10.1242/jcs.066654
|
[8]
|
Kamekura, R., Kolegraff, K.N., Nava, P., Hilgarth, R.S., Feng, M., Parkos, C.A. and Nusrat, A. (2014) Loss of the Desmosomal Cadherin Desmoglein-2 Suppresses Colon Cancer Cell Prolifera-tion through EGFR Signaling. Oncogene, 33, 4531-4536. https://doi.org/10.1038/onc.2013.442
|
[9]
|
Biedermann, K., Vogelsang, H., Becker, I., Plaschke, S., Siewert, J.R., Höfler, H. and Keller, G. (2005) Desmoglein 2 Is Expressed Abnormally Rather than Mutated in Familial and Sporadic Gastric Cancer. The Journal of Pathology, 207, 199-206. https://doi.org/10.1002/path.1821
|
[10]
|
Han, C.P., Yu, Y.H., Wang, A.G., Tian, Y., Zhang, H.T., Zheng, Z.M. and Liu, Y.S. (2018) Desmoglein-2 Overexpression Predicts Poor Prognosis in Hepatocellular Carcinoma Patients. European Review for Medical and Pharmacological Sciences, 22, 5481-5489.
|
[11]
|
Liu, Y.Q., Chu, L.Y., Yang, T., Zhang, B., Zheng, Z.T., Xie, J.J., Xu, Y.W. and Fang, W.K. (2022) Serum DSG2 as a Potential Biomarker for Diagnosis of Esophageal Squamous Cell Carcinoma and Esophagogastric Junction Adenocarcinoma. Bioscience Reports, 42, BSR20212612. https://doi.org/10.1042/BSR20212612
|
[12]
|
Xu, Y.-W., Peng, Y.-H., Chen, B., Wu, Z.-Y., Wu, J.-Y., Shen, J.-H., Zheng, C.-P., Wang, S.-H., Guo, H.-P., Li, E.-M. and Xu, L.-Y. (2014) Autoantibodies as Potential Biomarkers for the Early Detection of Esophageal Squamous Cell Carcinoma. The American Journal of Gastroenterolo-gy, 109, 36-45. https://doi.org/10.1038/ajg.2013.384
|
[13]
|
Zhang, H.-F., Qin, J.-J., Ren, P.-F., Shi, J.-X., Xia, J.-F., Ye, H., Wang, P., Song, C.-H., Wang, K.-J. and Zhang, J.-Y. (2016) A Panel of Autoantibodies against Multiple Tu-mor-Associated Antigens in the Immunodiagnosis of Esophageal Squamous Cell Cancer. Cancer Immunology, Immu-notherapy, 65, 1233-1242.
https://doi.org/10.1007/s00262-016-1886-6
|
[14]
|
Johnson, M.A. and Firth, S.M. (2014) IGFBP-3: A Cell Fate Pivot in Cancer and Disease. Growth Hormone & IGF Research, 24, 164-173. https://doi.org/10.1016/j.ghir.2014.04.007
|
[15]
|
Regel, I., Eichenmüller, M., Joppien, S., Liebl, J., Häberle, B., Müller-Höcker, J., Vollmar, A., von Schweinitz, D. and Kappler, R. (2012) IGFBP3 Impedes Aggressive Growth of Pe-diatric Liver Cancer and Is Epigenetically Silenced in Vascular Invasive and Metastatic Tumors. Molecular Cancer, 11, Article No. 9.
https://doi.org/10.1186/1476-4598-11-9
|
[16]
|
Zeng, L., Jarrett, C., Brown, K., Gillespie, K.M., Holly, J.M. and Perks, C.M. (2013). Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) Plays a Role in the Anti-Tumorigenic Ef-fects of 5-Aza-2’-Deoxycytidine (AZA) in Breast Cancer Cells. Experimental Cell Research, 319, 2282-2295.
https://doi.org/10.1016/j.yexcr.2013.06.011
|
[17]
|
Pernía, O., Belda-Iniesta, C., Pulido, V., Cortes-Sempere, M., Rodriguez, C., Vera, O., Soto, J., Jiménez, J., Taus, A., Rojo, F., Arriola, E., Rovira, A., Albanell, J., Macías, M.T., de Castro, J., Perona, R. and de Caceres, I.I. (2014) Methylation Status of IGFBP-3 as a Useful Clinical Tool for Deciding on a Concomitant Radiotherapy. Epigenetics, 9, 1446-1453. https://doi.org/10.4161/15592294.2014.971626
|
[18]
|
Ding, T.-Y., Peng, Y.-H., Hong, C.-Q., Huang, B.-L., Liu, C.-T., Luo, Y., Chu, L.-Y., Zhang, B., Li, X.-H., Qu, Q.-Q., Xu, Y.-W. and Wu, F.-C. (2022) Serum Insulin-Like Growth Factor Binding Protein 3 as a Promising Diagnostic and Prognostic Biomarker in Esophagogastric Junction Ad-enocarcinoma. Discover Oncology, 13, Article No. 128.
https://doi.org/10.1007/s12672-022-00591-1
|
[19]
|
Rice, T.W., Ishwaran, H., Hofstetter, W.L., Kelsen, D.P., Ap-person-Hansen, C. and Blackstone, E.H., for the worldwide Esophageal Cancer Collaboration Investigators (2016) Rec-ommendations for Pathologic Staging (pTNM) of Cancer of the Esophagus and Esophagogastric Junction for the 8th edi-tion AJCC/UICC Staging Manuals. Diseases of the Esophagus, 29, 897-905. https://doi.org/10.1111/dote.12533
|
[20]
|
Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., Miller, M.L., Rekhtman, N., Moreira, A.L., Ibrahim, F., Bruggeman, C., Gasmi, B., Zappasodi, R., Maeda, Y., Sander, C., Garon, E.B., et al. (2015) Mutational Landscape Determines Sensi-tivity to PD-1 Blockade in Non-Small Cell Lung Cancer. Science, 348, 124-128. https://doi.org/10.1126/science.aaa1348
|
[21]
|
Chan, A.W.H., Tong, J.H.M., Kwan, J.S.H., Chow, C., Chung, L.Y., Chau, S.L., Lung, R.W.M., Ng, C.S.H., Wan, I.Y.P., Mok, T.S.K. and To, K.F. (2018) Assessment of Programmed Cell Death Ligand-1 Expression by 4 Diagnostic Assays and Its Clinicopathological Correlation in a Large Cohort of Surgical Resected Non-Small Cell Lung Carcinoma. Modern Pathology, 31, 1381-1390. https://doi.org/10.1038/s41379-018-0053-3
|
[22]
|
Sanmamed, M.F. and Chen, L. (2014) Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation. Cancer Journal, 20, 256-261. https://doi.org/10.1097/PPO.0000000000000061
|
[23]
|
Patel, S.P. and Kurzrock, R. (2015) PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics, 14, 847-856. https://doi.org/10.1158/1535-7163.MCT-14-0983
|
[24]
|
Chen, Y., Wang, Q., Shi, B., Xu, P., Hu, Z., Bai, L. and Zhang, X. (2011) Development of a Sandwich ELISA for Evaluating Soluble PD-L1 (CD274) in Human Sera of Dif-ferent Ages as Well as Supernatants of PD-L1+ Cell Lines. Cytokine, 56, 231-238. https://doi.org/10.1016/j.cyto.2011.06.004
|
[25]
|
Shigemori, T., Toiyama, Y., Okugawa, Y., Yamamoto, A., Yin, C., Narumi, A., Ichikawa, T., Ide, S., Shimura, T., Fujikawa, H., Yasuda, H., Hiro, J., Yoshiyama, S., Ohi, M., Araki, T. and Kusunoki, M. (2019) Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression. Annals of Surgical Oncology, 26, 876-883.
https://doi.org/10.1245/s10434-018-07112-x
|
[26]
|
Fan, Y., Che, X., Qu, J., Hou, K., Wen, T., Li, Z., Li, C., Wang, S., Xu, L., Liu, Y. and Qu, X. (2019) Exosomal PD-L1 Retains Immunosuppressive Activity and Is Associated with Gastric Cancer Prognosis. Annals of Surgical Oncology, 26, 3745-3755. https://doi.org/10.1245/s10434-019-07431-7
|
[27]
|
Gershtein, E.S., Ognerubov, N.A., Chang, V.L., Delektorskaya, V.V., Korotkova, E.A., Sokolov, N.Y., Polikarpova, S.B., Stilidi, I.S. and Kushlinskii, N.E. (2020) The Content of the Soluble Forms PD-1 and PD-L1 in Blood Serum of Patients with Gastric Cancer and Their Relationship with Clinical and Morphological Characteristics of the Disease. Klinicheskaia Laboratornaia Diagnostika, 65, 347-352. https://doi.org/10.18821/0869-2084-2020-65-6-347-352
|
[28]
|
Shiraishi, T., Toyozumi, T., Sakata, H., Murakami, K., Kano, M., Matsumoto, Y., Yokoyama, M., Okada, K., Kamata, T., Ryuzaki, T., Kinoshita, K., Hirasawa, S. and Matsubara, H. (2022) Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associ-ated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma. Oncology, 100, 39-47. https://doi.org/10.1159/000518740
|
[29]
|
Wu, W., Xia, X., Cheng, C., Niu, L., Wu, J. and Qian, Y. (2021) Serum Soluble PD-L1, PD-L2 and B7-H5 as Potential Diagnostic Biomarkers of Human Pancreatic Cancer. Clinical Laboratory, 67.
https://doi.org/10.7754/Clin.Lab.2021.210103
|
[30]
|
Chen, K., Wang, X., Yang, L. and Chen, Z. (2021) The An-ti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review. Cancer Control, 28.
https://doi.org/10.1177/1073274821997430
|
[31]
|
Formica, V., Morelli, C., Patrikidou, A., Shiu, K.K., Nardecchia, A., Lucchetti, J., Roselli, M. and Arkenau, H.T. (2021) A Systematic Review and Meta-Analysis of PD-1/PD-L1 Inhib-itors in Specific Patient Subgroups with Advanced Gastro-Oesophageal Junction and Gastric Adenocarcinoma. Critical Reviews in Oncology/Hematology, 157, Article ID: 103173. https://doi.org/10.1016/j.critrevonc.2020.103173
|
[32]
|
Oh, S., Kim, E. and Lee, H. (2021) Comparative Impact of PD-1 and PD-L1 Inhibitors on Advanced Esophageal or Gastric/Gastroesophageal Junction Cancer Treatment: A Sys-tematic Review and Meta-Analysis. Journal of Clinical Medicine, 10, Artticle 3612. https://doi.org/10.3390/jcm10163612
|
[33]
|
Thompson, E.D., Zahurak, M., Murphy, A., Cornish, T., Cuka, N., Ab-delfatah, E., Yang, S., Duncan, M., Ahuja, N., Taube, J.M., Anders, R.A. and Kelly, R.J. (2017) Patterns of PD-L1 Ex-pression and CD8 T Cell Infiltration in Gastric Adenocarcinomas and Associated Immune Stroma. Gut, 66, 794-801. https://doi.org/10.1136/gutjnl-2015-310839
|
[34]
|
Mitchell, P.S., Parkin, R.K., Kroh, E.M., Fritz, B.R., Wyman, S.K., Pogosova-Agadjanyan, E.L., Peterson, A., Noteboom, J., O’Briant, K.C., Allen, A., Lin, D.W., Urban, N., Drescher, C.W., Knudsen, B.S., Stirewalt, D.L., Gentleman, R., Vessella, R.L., Nelson, P.S., Martin, D.B. and Tewari, M. (2008) Circulating microRNAs as Stable Blood-Based Markers for Cancer Detection. Proceedings of the National Academy of Sciences of the United States of America, 105, 10513-10518. https://doi.org/10.1073/pnas.0804549105
|
[35]
|
Liu, H., Zhu, L., Liu, B., Yang, L., Meng, X., Zhang, W., Ma, Y. and Xiao, H. (2012) Genome-Wide microRNA Profiles Identify miR-378 as a Serum Biomarker for Early Detection of Gastric Cancer. Cancer Letters, 316, 196-203.
https://doi.org/10.1016/j.canlet.2011.10.034
|
[36]
|
Liu, R., Zhang, C., Hu, Z., Li, G., Wang, C., Yang, C., Huang, D., Chen, X., Zhang, H., Zhuang, R., Deng, T., Liu, H., Yin, J., Wang, S., Zen, K., Ba, Y. and Zhang, C.Y. (2011) A Five-microRNA Signature Identified from Genome-Wide Serum microRNA Expression Profiling Serves as a Fingerprint for Gastric Cancer Diagnosis. European Journal of Cancer, 47, 784-791. https://doi.org/10.1016/j.ejca.2010.10.025
|
[37]
|
Wang, J., Zhang, H., Zhou, X., Wang, T., Zhang, J., Zhu, W., Zhu, H. and Cheng, W. (2018) Five Serum-Based miRNAs Were Identified as Potential Diagnostic Biomarkers in Gastric Cardia Adenocarcinoma. Cancer Biomarkers, 23, 193-203. https://doi.org/10.3233/CBM-181258
|
[38]
|
Tokunaga, R., Imamura, Y., Nakamura, K., Uchihara, T., Ishimoto, T., Nakagawa, S., Iwatsuki, M., Baba, Y., Sakamoto, Y., Miyamoto, Y., Yoshida, N., Oyama, S., Shono, T., Naoe, H., Saeki, H., Oki, E., Watanabe, M., Sasaki, Y., Maehara, Y. and Baba, H. (2015) Carbohydrate Antigen 19-9 Is a Useful Prognostic Marker in Esophagogastric Junction Adenocar-cinoma. Cancer Medicine, 4, 1659-1666. https://doi.org/10.1002/cam4.514
|
[39]
|
Scarpa, M., Noaro, G., Saadeh, L., Cavallin, F., Cagol, M., Alfieri, R., Plebani, M. and Castoro, C. (2015) Esophageal Cancer Management: Preoperative CA19.9 and CEA Serum Levels May Identify Occult Advanced Adenocarcinoma. World Journal of Surgery, 39, 424-432. https://doi.org/10.1007/s00268-014-2835-1
|